ClinicalTrials.gg
Not yet recruitingNCT07172945SUIVITHEQUE2Updated Sep 15, 2025

Research and Follow-up of the Determinants of the Progression and Complications of Inflammatory Bowel Diseases Treated or Not With Immunosuppressants.

An interventional study of Blood, fecal, saliva and intestinal content samples and biopsies in Crohn, Ulcerative Colitis (UC) and IBD (Inflammatory Bowel Disease), sponsored by Assistance Publique - Hôpitaux de Paris. Not yet recruiting. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-09-15.

Sponsored by Assistance Publique - Hôpitaux de Paris · Not applicable, Interventional, and Basic science

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
4,500
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 10 studies in Colitis, Ulcerative by Assistance Publique - Hôpitaux de Paris — 6 open to participants now, 7 under way, 1 of them phase 3. Colitis, Ulcerative · Assistance Publique - Hôpitaux de Paris.

Started
2025
with 1 other
No phase
2 of 10
1 open now
Registered
8th of 10
by date

Among the 10 studies in Colitis, Ulcerative by Assistance Publique - Hôpitaux de Paris, this one is one of 2 that started in 2025, is one of 2 with no phase, and was the 8th registered.

Colitis, Ulcerative

1,857 studies on the registry are indexed under Colitis, Ulcerative; 472 are open to participants now.

Browse Colitis, Ulcerative studies →

Open to participants now

6 of the 10 studies in Colitis, Ulcerative by Assistance Publique - Hôpitaux de Paris are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 305 Colitis, Ulcerative studies recruiting now, 135 (44%) set no upper age limit and 134 (44%) stop at 75 or younger; 70 take children under 18; 41 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Colitis, Ulcerative by Assistance Publique - Hôpitaux de Paris, or all of them as a file.
02

Study summary

Inflammatory Bowel Diseases (IBD), including Crohn's disease (CD) and ulcerative colitis (UC), are chronic, disabling conditions affecting young adults, marked by flare-ups and remissions. Traditionally, IBD was treated with immunosuppressants like thiopurines, but new biological treatments, such as anti-TNFa antibodies (e.g., infliximab, adalimumab), have transformed management. Biologics often combine with thiopurines but come with risks, like increased chances of skin cancers and lymphomas, especially for prolonged use in young patients. Recently, newer biologics (e.g., ustekinumab, vedolizumab) and small molecules like JAK inhibitors have expanded treatment options.

The exact cause of IBD remains unknown, though an inappropriate immune response to the intestinal microbiota in genetically predisposed individuals is suspected. Dysbiosis, or imbalance in gut microbiota, has been linked to IBD, with reductions in 'beneficial' bacteria and increases in harmful ones. Certain bacteria, like Faecalibacterium prausnitzii, may serve as markers for disease activity or progression.

Due to the heterogeneity of UC and CD, it is crucial to identify early predictive factors for complications and treatment response. This study aims to identify biological markers of disease course and complications in IBD and to deepen understanding of its pathophysiological mechanisms.

Read the detailed description

Inflammatory Bowel Diseases (IBD) are chronic, disabling conditions that affect young adults with a predilection for flare-ups interspersed with periods of remission. Crohn's disease (CD) and ulcerative colitis (UC) are the two main types of IBD.

IBD is a chronic disease, the course of which is often marked by complications. Until recently, the medical treatment of IBD was based on the use of immunosuppressants, particularly thiopurines. The management of IBD has been modified in recent years by the appearance of new so-called 'biological' treatments. Anti-TNFa antibodies (such as infliximab or adalimumab) represent, highly effective weapon in the arsenal available for treating IBD. Biological treatments appear to have a synergistic effect with thiopurines and their administration is therefore often concomitant. These immunosuppressive and biological treatments are not harmless, especially as they are taken for prolonged periods by young patients. In particular, the use of thiopurines is associated with a marked increase in the risk of non-melanoma skin cancers and lymphomas. The long-term risks of biological treatments are still poorly understood. For the treatment of IBD, there are now much more biologics available, including Ustekinumab, vedolizumab and also small molecules, such as JAK inhibitors.

Despite recent advances, the cause of IBD remains unknown. The currently dominant hypothesis is that of an inappropriate immune response to the intestinal microbiota in genetically predisposed individuals.

In humans, an imbalance in the composition of the intestinal microbiota (dysbiosis) has been demonstrated in patients with CD and UC, with a reduction in 'beneficial' bacteria and an increase in potentially 'harmful' bacteria. Finally, certain bacteria in the intestinal microbiota could be used as a marker of disease activity or as a predictive factor for progression, as we have shown with the Faecalibacterium prausnitzii bacterium and postoperative recurrence of Crohn's disease.

Given the phenotypic heterogeneity of UC and CD in terms of progression and complications, it is essential to identify predictive factors that will enable patients at risk to be identified as early as possible so that treatment can be adapted at an early stage.

Given the clinical and pathophysiological heterogeneity of IBD, it would seem difficult to use clinical factors alone to predict patient outcome. On the other hand, it would also be very important to be able to predict the response or side-effects of a treatment before starting it, which again would enable appropriate decisions to be made without wasting time. It therefore seems necessary to look for biological determinants of the course and complications of IBD.

The aims of the study are (i) to identify biological determinants of the course, complications and response to treatment of chronic inflammatory bowel disease and (ii) to gain a better understanding of the underlying pathophysiological mechanisms.

The primary outcome is to describe the Biological parameters of the host and microbiota as a prognosis factor, and the response to treatment in IBD.

The secondary outcomes are lister below:

  • Identification of genetic polymorphisms
  • Identification of serum markers
  • Identification of iImmune characteristics of the intestinal microbiota
  • Identification of markers of the intestinal microbiota
  • Mucosal characteristics of the intestinal microbiota
  • Mucosal markers of the intestinal microbiota
  • Mechanistic analysis: Exploratory study into the pathophysiology of host-microbiota interactions; interactions between epithelial cells, immune cells and micro-organisms and omics analysis including microbiome sequencing, transcriptomics, metabolomics, and functional assay will be perform to analyze the interactions between epithelial or immune cells with the gut microbiome
03

Conditions studied

  • Crohn
  • Ulcerative Colitis (UC)
  • IBD (Inflammatory Bowel Disease)

Keywords

  • Microbiome
  • Biobank
  • Crohn
  • Ulcerative colitis
  • IBD
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

For all patients and control subjects

  • Person able to give free and .
  • Age ≥ 18 years.
  • Beneficiary of a social protection scheme or entitled person (excluding AME).
  • Consultation in the Gastroenterology and Nutrition Department of Saint-Antoine Hospital

Patients with IBD :

- Patients with Crohn's disease or haemorrhagic rectocolitis with a diagnosis established or confirmed in the Gastroenterology and Nutrition Department at Saint-Antoine Hospital.

Microbiota control' subjects:

- Healthy subjects seen in consultation as a preventive measure or as part of stool donations for FMT.

Endoscopy control' subjects:

- Subjects with a medical indication for digestive endoscopy with :

  • For upper endoscopy: moderate upper digestive symptoms such as epigastralgia or pyrosis
  • For colonoscopy: moderate digestive symptoms suggestive of irritable bowel syndrome or screening for colorectal cancer.

Exclusion criteria

Exclusion Criteria:

For all patients and control subjects

  • Subjects under guardianship, curatorship or safeguard of justice.
  • Subjects who do not speak French.

IBD patients:

- Colon preparation within 6 weeks before stool sampling (stool samples may be taken either before colonoscopy or at least 6 weeks afterwards).

Endoscopy control' and "microbiota control" subjects:

  • Subject suffering from a chronic disease
  • Antibiotics taken in the 6 weeks prior to endoscopy
  • Antibiotics or colonic preparation taken within 6 weeks prior to stool sampling (stool samples may be taken either before colonoscopy or at least 6 weeks afterwards).
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
4,500 participants (estimated)

Study arms

  • Other
    Patients with Inflammatory Bowel Diseases

    Other: Blood, fecal, saliva · Other: intestinal content samples and biopsies

  • Other
    Microbiota control' subjects

    Other: Blood, fecal, saliva

  • Other
    Endoscopy control' subjects

    Other: Blood, fecal, saliva · Other: intestinal content samples and biopsies

Interventions

  • OtherBlood, fecal, saliva

    Blood, fecal and saliva samples

  • Otherintestinal content samples and biopsies

    intestinal content samples and biopsies obtained per upper or lower gastrointestinal tract endoscopy

06

What researchers measure

Primary outcomes

  1. Relation between biological parameters (fecal and ileal microbiome) and outcomes of IBD

    identify relations between fecal and ileal microbiome and disease evolution

    Time frame: up to 12 months after the inclusion

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Yes — plans to share these data outside the primary research group for secondary research purposes like re-analysis, secondary analysis, or meta-analysis. Data may be shared via an online platform, an email request, nonelectronic transfer, or other method

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Sep 2025; primary completion for Nov 2040, 182 months later.

Of 228 non-industry interventional studies with no phase under Colitis, Ulcerative, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 56. This study's planned 182 months is above that.

Counting every sponsor, half of 239 studies reached it within 34 months; a quarter within 15 and three quarters within 52.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 21, 2024
First posted
Sep 15, 2025
StartEst.
Sep 2025
Primary completionEst.
Nov 2040
CompletionEst.
Nov 2040
Last update
Sep 15, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 15, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07172945
Collaborators
Sorbonne University
Responsible party
Sponsor
First posted
Sep 15, 2025
Start date
Sep 2025 (estimated)
Primary completion
Nov 2040 (estimated)
Completion
Nov 2040 (estimated)
Last update
Sep 15, 2025

Study contacts

Harry SOKOL, MD, PhD01
Contact
harry.sokol@aphp.fr
+ 33 1 49 28 31 62
Philippe Seksik, MD, PhD
Contact
philippe.seksik@aphp.fr
+ 33 1 49 28 31 62
Harry SOKOL, Professor
principal investigator · Assistance Publique - Hôpitaux de Paris

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion